country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P991958

Copy Link Print Information

GIGA-564

GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a K_d of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

GIGA-564 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Species Reactivity

Human

In Vitro

GIGA-564 (0.001-100 μg/mL) exhibits extremely low activity in blocking the binding of CTLA-4 to CD80 and CD86 in ELISA assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GIGA-564 (5 mg/kg; i.p.; once every 3 days; 3 doses) induces a lower level of peripheral Treg proliferation than Ipilimumab (HY-P9901) in hCTLA-4 KI mice bearing MC38 tumors^[1].
GIGA-564 (0.3 mg/kg; i.p.; once every 3 days; 3 doses) exhibits excellent anti-tumor activity in hCTLA-4 KI mice bearing MC38 tumors^[1].
GIGA-564 (30 mg/kg; i.p.; once every 3 days; 9 doses) induces less toxicity than Ipilimumab (HY-P9901) in hCTLA-4 knock-in (KI) and hCTLA-4/hPD-1 double knock-in (KI) mice, as evidenced by lower liver enzyme levels, reduced colitis, and the absence of skin lesions at the tested dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

hCTLA-4 KI (implanted with MC38 tumor cells)^[1]
Dosage:

0.3 mg/kg
Administration:

i.p.; once every 3 days; 3 doses
Result:

Resulted in significantly smaller tumor volumes, with a significantly lower mean tumor volume at day 25 compared to ipilimumab and isotype control.
Improved survival probability.

Gene ID

1493 [NCBI]

Accession

P16410

Target

CTLA4

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Application

ELISA, FACS, Functional assay

Chemical Information

SMILES

[GIGA-564]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Stone E L, et al. GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models//JOURNAL FOR IMMUNOTHERAPY OF CANCER. BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: BMJ PUBLISHING GROUP, 2022, 10: A1443-A1443.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock

Amount: USD 0.00

Activité biologique
- Description
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

GIGA-564

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

GIGA-564 Related Classifications

HY-P991958 Related Classifications